WAT outlook supported by localization, pricing and integration momentum
TradingView reports strong Q2 results led by growth across instruments, recurring revenue and chemistry. China and pharma segments outperformed, while localization, pricing improvements and integration synergies support sustained high single-digit growth through 2…
Strong Q2 results were driven by broad growth across instruments, recurring revenue and chemistry, with China and pharma segments outperforming expectations. Localization, pricing improvements and integration synergies are supporting momentum and pointing to sustained high single-digit growth through 2…